These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 20716744)

  • 1. Minimizing bias in randomized trials: the importance of blinding.
    Psaty BM; Prentice RL
    JAMA; 2010 Aug; 304(7):793-4. PubMed ID: 20716744
    [No Abstract]   [Full Text] [Related]  

  • 2. Importance of blinding in randomized trials.
    Strite SA; Stuart ME
    JAMA; 2010 Nov; 304(19):2127-8; author reply 2128. PubMed ID: 21081725
    [No Abstract]   [Full Text] [Related]  

  • 3. Blinding in randomized clinical trials: imposed impartiality.
    Hróbjartsson A; Boutron I
    Clin Pharmacol Ther; 2011 Nov; 90(5):732-6. PubMed ID: 21993424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The blind leading the blind: use and misuse of blinding in randomized controlled trials.
    Miller LE; Stewart ME
    Contemp Clin Trials; 2011 Mar; 32(2):240-3. PubMed ID: 21070890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Who is blinded in randomized clinical trials? A study of 200 trials and a survey of authors.
    Haahr MT; Hróbjartsson A
    Clin Trials; 2006; 3(4):360-5. PubMed ID: 17060210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assuring that double-blind is blind.
    Perlis RH; Ostacher M; Fava M; Nierenberg AA; Sachs GS; Rosenbaum JF
    Am J Psychiatry; 2010 Mar; 167(3):250-2. PubMed ID: 20194487
    [No Abstract]   [Full Text] [Related]  

  • 7. Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid.
    Akl EA; Sun X; Busse JW; Johnston BC; Briel M; Mulla S; You JJ; Bassler D; Lamontagne F; Vera C; Alshurafa M; Katsios CM; Heels-Ansdell D; Zhou Q; Mills E; Guyatt GH
    J Clin Epidemiol; 2012 Mar; 65(3):262-7. PubMed ID: 22200346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How well does blinding work in randomized controlled trials?: a counterpoint.
    Boehmer J; Yong P
    Clin Pharmacol Ther; 2009 May; 85(5):463-5. PubMed ID: 19381149
    [No Abstract]   [Full Text] [Related]  

  • 9. Practical aspects of randomization and blinding in randomized clinical trials.
    Bridgman S; Engebretsen L; Dainty K; Kirkley A; Maffulli N;
    Arthroscopy; 2003 Nov; 19(9):1000-6. PubMed ID: 14608321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An observational study found that authors of randomized controlled trials frequently use concealment of randomization and blinding, despite the failure to report these methods.
    Devereaux PJ; Choi PT; El-Dika S; Bhandari M; Montori VM; Schünemann HJ; Garg AX; Busse JW; Heels-Ansdell D; Ghali WA; Manns BJ; Guyatt GH
    J Clin Epidemiol; 2004 Dec; 57(12):1232-6. PubMed ID: 15617948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of clinical data with breached blindness.
    Chow SC; Shao J
    Stat Med; 2004 Apr; 23(8):1185-93. PubMed ID: 15083477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the need for objective measures of risk of bias.
    Berger VW; Mickenautsch S
    Contemp Clin Trials; 2015 Mar; 41():202-3. PubMed ID: 25666855
    [No Abstract]   [Full Text] [Related]  

  • 13. Participant expectancies in double-blind randomized placebo-controlled trials: potential limitations to trial validity.
    Colagiuri B
    Clin Trials; 2010 Jun; 7(3):246-55. PubMed ID: 20421243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A critique of the double-blind clinical trial. Part 1.
    Kiene H
    Altern Ther Health Med; 1996 Jan; 2(1):74-80. PubMed ID: 8795875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The quality of reporting of orthopaedic randomized trials with use of a checklist for nonpharmacological therapies.
    Chan S; Bhandari M
    J Bone Joint Surg Am; 2007 Sep; 89(9):1970-8. PubMed ID: 17768194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blinding: an essential component in decreasing risk of bias in experimental designs.
    Forbes D
    Evid Based Nurs; 2013 Jul; 16(3):70-1. PubMed ID: 23696228
    [No Abstract]   [Full Text] [Related]  

  • 17. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 1: fundamentals of study design.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e302-4. PubMed ID: 15173052
    [No Abstract]   [Full Text] [Related]  

  • 18. Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding.
    Hróbjartsson A; Forfang E; Haahr MT; Als-Nielsen B; Brorson S
    Int J Epidemiol; 2007 Jun; 36(3):654-63. PubMed ID: 17440024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blinding in randomised trials: hiding who got what.
    Schulz KF; Grimes DA
    Lancet; 2002 Feb; 359(9307):696-700. PubMed ID: 11879884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electronic health records may threaten blinding in trials of statins.
    Nguyen Pv
    BMJ; 2014 Aug; 349():g5239. PubMed ID: 25143525
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.